Overview
CJC-1295 (No DAC), known in the literature as Modified GRF (1-29), is a synthetic analog of the first 29 amino acids of growth hormone-releasing hormone — the shortest sequence that keeps full activity at the GHRH receptor. It is deliberately built without the Drug Affinity Complex, so it clears quickly and produces brief, pulse-like receptor stimulation rather than sustained exposure. That transient profile is precisely what makes it valuable for growth hormone secretion dynamics and pulse-modeling experiments.
Mechanism of Action
In cell-based and preclinical models, CJC-1295 (No DAC) agonizes GHRHR on pituitary somatotrophs, activating adenylyl cyclase and raising intracellular cAMP through a Gs/PKA cascade that drives calcium-dependent exocytosis of stored growth hormone. Engineered amino-acid substitutions improve resistance to DPP-IV degradation relative to native GRF(1-29). Because this cAMP pathway is pharmacologically distinct from the Gq/11 calcium signaling engaged by GHS-R1a agonists such as Ipamorelin, the two compounds are frequently paired in dual-secretagogue synergy designs.
Specifications
- Purity: ≥99% (HPLC) with mass-spectrometry identity confirmation
- Form: Lyophilized powder
- CAS Number: 446036-97-1
- Molecular Weight: ~3367.9 g/mol
- Chemical Formula: C₁₅₂H₂₅₂N₄₄O₄₂
- Synonyms: Modified GRF (1-29), Mod GRF 1-29, CJC-1295 without DAC
Research Applications
- GHRH receptor binding and activation studies
- Pulsatile GH-release and secretion dynamics modeling
- cAMP/PKA signaling pathway research
- Dual-secretagogue synergy studies with GHS-R1a agonists
- GHRH analog stability and enzymatic degradation research





